In most of human prolactin (PRL)-secreting adenomas, dopamine and dopamine agonists normally suppress the excessive PRL secretion. Nevertheless, a subpopulation of such patients presents a relative insensitivity to the ergot derivative bromocriptine. Six patients with a macroadenoma (n = 5) or microadenoma (n = 1) were considered resistant to bromocriptine which, at a daily dose of 15–60 mg, did not normalize high plasma PRL levels. Culture studies of these adenoma cells showed that: (1) 10–8M bromocriptine produced a 32 ± 16% inhibition of PRLrelease versus 65 ± 12% obtained in the same conditions with normal human pituitary cells; (2) sulpiride (10–6M) reversed the inhibitory effects of bromocriptine, and (3) the bacterial endotoxins, cholera toxin (l0–11M) and pertussis toxin (250 ng/ml), respectively, produced a 45–500% increase and a total abolition of bromocriptine induced PRLinhibition. These observations and recent data of the literature allow to discuss the possibility of receptor or postreceptor defects in such tumors.